News & Updates
Filter by Specialty:
ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).
ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
21 Sep 2022
Bimekizumab safety for moderate to severe plaque psoriasis affirmed
Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).
Bimekizumab safety for moderate to severe plaque psoriasis affirmed
20 Sep 2022
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
16 Sep 2022
Older age, itch, pain predict depression in atopic dermatitis
Depressive symptoms are common among adults with atopic dermatitis (AD) severity and may fluctuate over time, reveals a study. Persistent depression is significantly associated with older age, male sex, severe itch, and skin pain, among others.
Older age, itch, pain predict depression in atopic dermatitis
15 Sep 2022
Roflumilast shows treatment potential for seborrheic dermatitis
In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).
Roflumilast shows treatment potential for seborrheic dermatitis
15 Sep 2022
Low-dose methotrexate-related melanoma risk considered negligible
Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.